References
- 1. Attal M, Harouseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide imporves survival in patinets with multiple myeloma. Blood. 2006;108:3289-3294.10.1182/blood-2006-05-022962
- 2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemotherapy for multiple myeloma: Final results of a phase III US intergroup trail S9321. J Clin Oncol. 2006;24:929-936.10.1200/JCO.2005.04.5807
- 3. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014;124:328-333.10.1182/blood-2014-03-561985
- 4. Koreth J, Clutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma. A systematic review and meta-analysis of randomised controlled trials. Biol Blood Marrow Transplant. 2007;13:183-196.10.1016/j.bbmt.2006.09.010
- 5. Kroger N, Perez-Simon J, Myint H, et al. Influence of timing allogenic stem cell transplantation after dose-redused melphalan/fludarabine condition in multiple myeloma. Biol Blood and Marrow Transplant. 2004;10:698-708.10.1016/j.bbmt.2003.12.098
- 6. Moreau P, San Miguel J, Ludwig H. Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl6):vi133-137.10.1093/annonc/mdt297